Your browser doesn't support javascript.
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
Du, Yingying; Xu, Yuhua; Feng, Jin; Hu, Longbo; Zhang, Yanan; Zhang, Bo; Guo, Weili; Mai, Runming; Chen, Liyun; Fang, Jianmin; Zhang, Hui; Peng, Tao.
  • Du Y; Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Xu Y; Guangdong South China Vaccine, Guangzhou, China.
  • Feng J; Guangdong South China Vaccine, Guangzhou, China.
  • Hu L; Sino-French Hoffmann Institute of Immunology, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou, China.
  • Zhang Y; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Zhang B; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Guo W; Guangdong South China Vaccine, Guangzhou, China.
  • Mai R; Guangdong South China Vaccine, Guangzhou, China.
  • Chen L; Guangdong South China Vaccine, Guangzhou, China.
  • Fang J; Sino-French Hoffmann Institute of Immunology, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou, China.
  • Zhang H; Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China. Electronic address: zhangh92@mail.sysu.edu.cn.
  • Peng T; Guangdong South China Vaccine, Guangzhou, China; Sino-French Hoffmann Institute of Immunology, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou, China. Electronic address: peng_tao@gibh.ac.cn.
Vaccine ; 39(16): 2280-2287, 2021 04 15.
Article in English | MEDLINE | ID: covidwho-1118711
ABSTRACT
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Administration, Intranasal / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Topics: Vaccines Limits: Animals Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.03.006

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Administration, Intranasal / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Topics: Vaccines Limits: Animals Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.03.006